- $99.24m
- $68.35m
- $0.01m
Annual income statement for Genelux, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 11.1 | 0.17 | 0.008 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 12.4 | 14.6 | 13.8 | 24.7 | 31.3 |
| Operating Profit | -12.4 | -14.6 | -2.7 | -24.6 | -31.3 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -13.6 | -16.4 | -4.11 | -28.3 | -29.9 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -13.6 | -16.4 | -5.21 | -28.3 | -29.9 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -13.6 | -16.4 | -5.21 | -28.3 | -29.9 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | -13.6 | -16.4 | -5.21 | -28.3 | -29.9 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.577 | -0.695 | -0.593 | -1.14 | -0.961 |
| Dividends per Share |